| Literature DB >> 32425004 |
Qin Zhang1,2, Jian Pan1,2, Min-Xing Zhao1,2, Yuan-Qiang Lu1,2.
Abstract
Since the global outbreak of severe acute respiratory syndrome (SARS) in 2003, China has gradually built a robust prevention and control system for sudden infectious diseases. All large hospitals have a fever clinic that isolates patients with all kinds of acute communicable diseases as the first line of medical defense. The emergency department, as the second line of medical defense in hospitals, is constantly shouldering the heavy responsibility of screening communicable diseases while also treating all kinds of other non-communicable acute and critical diseases (Zhang et al., 2012; Zhu et al., 2015; Wang et al., 2017; Feng et al., 2018; Lu, 2018; Xu and Lu, 2019). An outbreak of pneumonia of unknown etiology that began in Wuhan city (China) has spread rapidly in China since December 2019 (Huang et al., 2020; WHO, 2020; Zhu et al., 2020). In February 2020, the National Health Commission of China named the disease a novel coronavirus pneumonia (NCP); then, it was formally named the coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO) on Feb. 11, 2020. The Coronavirus Study Group of the International Committee on Taxonomy of Viruses designated this causative virus as SARS coronavirus 2 (SARS-CoV-2). SARS-CoV-2 belongs to the β coronavirus genus, and its pathogenic mechanism has not been clarified, which requires further study. To better understand the clinical characteristics of COVID-19 and more effectively prevent and control this disease, we retrospectively analyzed four representative cases of COVID-19 that had recently been screened and diagnosed in our emergency department.Entities:
Keywords: Coronavirus disease 2019 (COVID-19); SARS-CoV-2; Emergency department
Mesh:
Year: 2020 PMID: 32425004 PMCID: PMC7089061 DOI: 10.1631/jzus.B2010011
Source DB: PubMed Journal: J Zhejiang Univ Sci B ISSN: 1673-1581 Impact factor: 3.066
Characteristic results of the patients with coronavirus disease 2019 (COVID-19) that underwent physical examination and laboratory investigation upon admission
| Patient |
|
|
| BP (mmHg) | WBC (cells/L) |
|
| CRP (mg/L) |
| Case 1 | 36.6 | 106 | 18 | 157/98 | 4.0 | 57.6 | 29.0 | 5.1 |
| Case 2 | 37.0 | 91 | 20 | 155/81 | 8.6 | 79.8 | 10.3 | 111.2 |
| Case 3 | 37.5 | 103 | 23 | 127/71 | 17.6 | 93.6 | 3.6 | 89.0 |
| Case 4 | 37.3 | 92 | 18 | 113/79 | 2.5 | 63.3 | 29.2 | 3.6 |
|
| ||||||||
| Reference range | 35.7–37.5 | 60–100 | 12–20 | (90–140)/(60–90) | 4.0×109–10.0×109 | 50.0–70.0 | 20.0–40.0 | 0.0–8.0 |
T: temperature; P: pulse; R: respiratory; BP: blood pressure; WBC: white blood cell; N: percent of neutrophils; L: percent of lymphocytes; CRP: C-reactive protein. 1 mmHg=133.3 Pa
Fig. 1Imaging studies of lung CT scans
(a) A nodular, dense shadow in the subpleural basal segment of the right lower lobe with halo sign and patchy consolidations under the pleura in the basal segment of both lower lungs with bronchial ventilation signs. (b) Multiple flaky and patchy ground-glass shadows with unclear edges and uneven densities, mainly in the peripheral and posterior lungs. (c) Multiple patchy ground-glass shadows and strip-like consolidations with unclear boundaries in both lungs, especially under the pleura. (d) Multiple small patchy and flaky ground-glass shadows in the left upper lung (mainly posterior and lingual) and posterior upper lobe and middle lobe (mainly medial) of the right lung, especially under the pleura. CT: computed tomography
Fig. 2Fluorescence detection of positive specimens from COVID-19 patients by rRT-PCR
A specimen is considered positive for COVID-19 if all COVID-19 markers (ORF1ab, IQC, N) cycle threshold growth curves cross the threshold line. COVID-19: coronavirus disease 2019; rRT-PCR: real-time reverse-transcriptase polymerase chain reaction; FAM: a reporter fluorescein dye targeting ORF1ab; ROX: a reporter fluorescein dye targeting IQC; VIC: a reporter fluorescein dye targeting N